Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
2011 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.
2007
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
2012
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
2010
EGFR Antagonists in Cancer Treatment
2008 Standout
Carbon nanotubes for delivery of small molecule drugs
2013
An Acquired and Endogenous Glycocalyx Forms a Bidirectional “Don’t Eat” and “Don’t Eat Me” Barrier to Phagocytosis
2020 StandoutNobel
Clinical development of liposome based drugs: formulation, characterization, and therapeutic efficacy
2011
A view on drug resistance in cancer
2019 StandoutNature
Management of RA medications in pregnant patients
2009
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Rheumatoid arthritis
2016 Standout
Pegylated liposomal doxorubicin: Proof of principle using preclinical animal models and pharmacokinetic studies
2004
Drug penetration in solid tumours
2006 Standout
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Liposome targeting to tumors using vitamin and growth factor receptors
2000
Biodegradable luminescent porous silicon nanoparticles for in vivo applications
2009 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Thermosensitive liposomes for localized delivery and triggered release of chemotherapy
2013
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Delivery materials for siRNA therapeutics
2013 Standout
Cardiac safety of liposomal anthracyclines
2007
Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic
2009
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
2010
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Soft-Tissue Sarcomas in Adults
2005 Standout
The role of new agents in the treatment of non-small cell lung cancer
2002
Cancer nanotechnology: opportunities and challenges
2005 Standout
Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points
2008
A structure-based computational workflow to predict liability and binding modes of small molecules to hERG
2020 StandoutNobel
Cancer genes and the pathways they control
2004 Standout
Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies
2005
Trastuzumab‐associated cardiotoxicity
2002
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
2012
Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects
2015
IKK/NF- B signaling: balancing life and death - a new approach to cancer therapy
2005 Standout
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer
2008
Liposome-based drug delivery in breast cancer treatment
2002
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Emerging Role of Liposomal Drug Carrier Systems in Cancer Chemotherapy
2003
Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet™)
2009
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2
2000
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy
2002
Tumor-Targeted Hyaluronan Nanoliposomes Increase the Antitumor Activity of Liposomal Doxorubicin in Syngeneic and Human Xenograft Mouse Tumor Models
2004
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Overview of the clinical efficacy of investigational anticancer drugs
2003
Rheumatoid arthritis
2010 Standout
Thalidomide
2004
Cardiovascular effects of systemic cancer treatment
2010
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
2000
Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin
2016
NF-κB as a therapeutic target in cancer
2002
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Kaposi's Sarcoma
2000 Standout
Cancer Chemotherapy and Cardiac Arrhythmias: A Review
2015
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Preservation of Fertility in Patients with Cancer
2009 Standout
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
2003
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper
2010
pH-responsive self-healing injectable hydrogel based on N-carboxyethyl chitosan for hepatocellular carcinoma therapy
2017
Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive and Rapidly Progressive Thyroid Carcinomas
2007
Minor Increases in Plasma Troponin I Predict Decreased Left Ventricular Ejection Fraction after High-Dose Chemotherapy
2003
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Direct Assessment of Drug Penetration into Tissue Using a Novel Application of Three-Dimensional Cell Culture
2004
Nanoparticle Delivery of Cancer Drugs
2011
Photoexpulsion of Surface-Grafted Ruthenium Complexes and Subsequent Release of Cytotoxic Cargos to Cancer Cells from Mesoporous Silica Nanoparticles
2013 StandoutNobel
Paclitaxel Is Safe and Effective in the Treatment of Advanced AIDS-Related Kaposi's Sarcoma
1999
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
2006 Standout
Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face
1999
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
2002 Standout
The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development
2011
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
AIDS-Related Malignancies
2003
Liposomal Formulations in Clinical Use: An Updated Review
2017 Standout
Liposomal anthracyclines for breast cancer
2001
From Conventional to Stealth Liposomes a new Frontier in Cancer Chemotherapy
2003
Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
2004 Standout
Functional Hydrogels as Wound Dressing to Enhance Wound Healing
2021 Standout
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group
2007
Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes
2005
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Liposomal daunorubicin as treatment for Kaposi's sarcoma.
2007
Cardiotoxicity of Cancer Therapy
2005
Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions
2013
Reduction of Retrovirus-Induced Immunosuppression by In Vivo Modulation of T Cells during Acute Infection
2004 StandoutNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Light-triggered switching of liposome surface charge directs delivery of membrane impermeable payloads in vivo
2020
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device
2021 StandoutNobel
Strategy for the treatment of acute myelogenous leukemia based on folate receptor β–targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid
2002
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
Advantages of liposomal delivery systems for anthracyclines
2004
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Clinical Translation of Nanomedicine
2015
In vivo targeting of B-cell lymphoma with glycan ligands of CD22
2010
Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities
2001
Works of Lauri Welles being referenced
Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy
2002
Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.
1998
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
2001
Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer
2003
Activity of Thalidomide in AIDS-Related Kaposi’s Sarcoma
2000
Cardiac safety and efficacy of TLC D99 (D99) and trastuzumab in patients with advanced breast cancer
2001
Developing Drugs to Decrease the Toxicity of Chemotherapy
2001
Phase II Trial of High-Dose Liposome-Encapsulated Doxorubicin With Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer
1999
Liposome-Encapsulated Doxorubicin in Combination With Standard Agents (cyclophosphamide, vincristine, prednisone) in Patients With Newly Diagnosed AIDS-Related Non-Hodgkin's Lymphoma: Results of Therapy and Correlates of Response
2004
Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies
2005